IFLR1000

Swedish Orphan Biovitrum $1.6 billion acquisition of US rights of Synagis

28/2/2019
Acquisition finance, Private acquisition
Select tab

$ 1.6 billion

Announced

28/2/2019

Overview:

  • Swedish Orphan Biovitrum (Sobi) has agreed to acquire the US rights to a treatment for infant lung infections to AstraZeneca for $1.6 billion.
  • To finance the transaction, Sobi took up new credit facilities provided by BNP Paribas, Danske Bank, Scandinavian Enskilda Banken and Svenska Handelsbanken.

Prin Shasiharan - Researcher

Jurisdictions:

United States
Sweden

Deal types:

Acquisition finance
Private acquisition

Practice areas:

Banking
M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:
Cederquist

Party: BNP Paribas (Lender)

Party: Danske Bank (Lender)

Party: SEB (Lender)

Party: Svenska Handelsbanken (Lender)

Lawyer: Johan Lundberg

Cirio

Party: AstraZeneca (Seller)

Lawyer: Maria Arnoldsson

Mannheimer Swartling

Party: Swedish Orphan Biovitrum (Borrower)

Related deals